Fletcher Building Limited (FBU.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 04:10PM AEST
Loading interactive chart…
- Simply Wall St.
Fletcher Building Limited's (NZSE:FBU) Intrinsic Value Is Potentially 79% Above Its Share Price
Does the May share price for Fletcher Building Limited ( NZSE:FBU ) reflect what it's really worth? Today, we will...
- Simply Wall St.
Should You Investigate Fletcher Building Limited (NZSE:FBU) At NZ$6.15?
Fletcher Building Limited ( NZSE:FBU ), might not be a large cap stock, but it received a lot of attention from a...
- GlobeNewswire
Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia
Phase 1 Trial of DT-216 in Patients with Friedreich Ataxia to Be Initiated Soon Topline Data from Phase 1 Trial Expected in the Second Half of 2022 CARLSBAD, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that its Investigational New Drug Application (IND) for its lead candidate, DT-216, for the treatment of Friedreich ataxia (FA), was cleared by the U.S. Food an
© 2022 Yahoo. All rights reserved.
